Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)

Pavord, Ian D.; Hoyte, Flavia C.L.; Lindsley, Andrew W.; Ambrose, Christopher S.; Spahn, Joseph D.; Roseti, Stephanie L.; Cook, Bill; Griffiths, Janet M.; Hellqvist, Åsa; Martin, Nicole; Llanos, Jean-Pierre; Martin, Neil; Colice, Gene; Corren, Jonathan

doi:10.1016/j.anai.2023.08.015

Cited by 10 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously highlighted the central role of TSLP in mediating mucosal inflammatory diseases of which ocular surface allergy and asthma are prime examples. In the phase 3 trial, Tezepelumab, a monoclonal antibody targeting TSLP, significantly minimized exacerbation of symptoms across all seasons in patients with uncontrolled asthma, including those with seasonal and perennial allergies ( Table 3 ) [ 213 ]. This therapy offers a promising therapeutic alternative in the treatment of seasonal and perennial allergic conjunctivitis.…”

Section: Cytokines As Therapeutic Targets In the Management Of Allerg...mentioning

confidence: 99%

Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles

Chigbu,

Karbach,

Abu

et al. 2024

Life

View full text Add to dashboard Cite

Allergic conjunctivitis is one of the common immune hypersensitivity disorders that affect the ocular system. The clinical manifestations of this condition exhibit variability contingent upon environmental factors, seasonal dynamics, and genetic predisposition. While our comprehension of the pathophysiological engagement of immune and nonimmune cells in the conjunctiva has progressed, the same cannot be asserted for the cytokines mediating this inflammatory cascade. In this review, we proffer a comprehensive description of interleukins 4 (IL-4), IL-5, IL-6, IL-9, IL-13, IL-25, IL-31, and IL-33, as well as thymic stromal lymphopoietin (TSLP), elucidating their pathophysiological roles in mediating the allergic immune responses on the ocular surface. Delving into the nuanced functions of these cytokines holds promise for the exploration of innovative therapeutic modalities aimed at managing allergic conjunctivitis.

show abstract

Section: Cytokines As Therapeutic Targets In the Management Of Allerg...mentioning

confidence: 99%

Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles

Chigbu,

Karbach,

Abu

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

“… 114 , 115 , 116 , 117 Interestingly, the results were not correlated with the participants' serum eosinophil count 115 and were equally effective in participants with associated allergic rhinitis (either seasonal or perennial). 118 …”

Section: Future Biologics For Chronic Eosinophilic Rhinosinusitismentioning

confidence: 99%

Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update

Anselmo-Lima,

Romano,

Tamashiro

et al. 2024

Brazilian Journal of Otorhinolaryngology

View full text Add to dashboard Cite

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study

Carr,

Moore,

Kraft

et al. 2024

Adv Ther

Self Cite

View full text Add to dashboard Cite

Introduction: Many patients with severe asthma continue to experience symptoms and exacerbations despite treatment with standardof-care therapy. In the phase 3 NAVIGATOR study, tezepelumab significantly reduced exacerbations over 52 weeks compared with placebo in patients with severe, uncontrolled asthma. This analysis assessed the efficacy of tezepelumab in reducing asthma exacerbations in various clinically relevant subgroups of patients in NAVIGATOR. Methods: NAVIGATOR was a phase 3, multicentre, randomized, double-blind, placebo-controlled study. Participants (12-80 years old) with severe, uncontrolled asthma were randomized 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Prespecified and post hoc analyses were performed to evaluate the annualized asthma exacerbation rate (AAER) over 52 weeks in clinically relevant subgroups of patients defined by baseline patient characteristics, medical history, exacerbation triggers, medication eligibility and medication use before and during the study. Results: Tezepelumab reduced the AAER over 52 weeks compared with placebo across a wide range of patient subgroups assessed. Reductions Adv Ther tezepelumab compared with placebo were also observed irrespective of exacerbation trigger category and the number of asthma controller medications patients were receiving at baseline. Conclusion: These findings further support the benefits of tezepelumab in patients with severe, uncontrolled asthma and can help to inform healthcare providers' treatment decisions. Clinical Trial Registration: NAVIGATOR (NCT03347279).

show abstract

Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)

Cited by 10 publications

References 40 publications

Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles

Cytokines in Allergic Conjunctivitis: Unraveling Their Pathophysiological Roles

Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study

Contact Info

Product

Resources

About